Ipsen Stock Drops Nearly 5% and Breaks Its Moving Averages

Ipsen Falls Below Its 50-Day Moving Average and Breaks Down Technical Support at €159.40

Ipsen's stock lost 4.76% to €158.10 during the session, among the sharpest declines in the SBF 120. The stock has fallen below its 20-day moving average at €165.04 and its 50-day moving average at €161.13, breaking the upward momentum of recent weeks.

The price is now below the lower Bollinger band, set at €158.67, indicating a potential oversold condition. However, the RSI at 52 remains neutral, suggesting that today's decline does not yet reflect a fundamental shift. The identified support at €159.40 was breached during the session, with the next technical zone significantly lower. Conversely, the 200-day moving average at €133.83 remains well below the current price, and the stock still shows a gain of 53.5% over one year.

The decline occurs in a session of general tension on risk assets, with U.S. bond yields at their highest since February 2025 and Brent crude above $110.

Governance, Clinical Pipeline, and Financial Calendar Shape the Company's News

On the corporate side, Ipsen announced the resignation of Karen Witts from the board of directors, effective at the end of the general meeting on May 13, 2026. Pascal Touchon will serve as interim chair of the audit committee. The company also announced the presentation of phase II data on corabotase, a recombinant neuro-inhibitor candidate, at the SCALE symposium on May 16, 2026.

As a reminder, the first quarter 2026 revenue reached €1,074.9 million, up 22.6% at constant exchange rates, and the annual guidance (growth over 13%) was confirmed. Based on the consensus of eight analysts, the stock is trading at about 11.5 times the expected earnings for the current fiscal year, compared to a 'Health Care' sector average of 21.9 times. The next financial event is scheduled for July 30, 2026, with the publication of the first semester results.